Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer.
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Apoptosis
/ genetics
Carcinoma, Pancreatic Ductal
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ genetics
Datasets as Topic
Drug Resistance, Neoplasm
/ genetics
Gene Expression Regulation, Neoplastic
/ immunology
Gene Knock-In Techniques
Gene Knockdown Techniques
Humans
Intracellular Signaling Peptides and Proteins
/ genetics
Kaplan-Meier Estimate
Pancreas
/ immunology
Pancreatic Neoplasms
/ drug therapy
Primary Cell Culture
Prognosis
Protein Processing, Post-Translational
/ immunology
RNA-Seq
Voltage-Dependent Anion Channel 2
/ genetics
Chemotherapy resistance
IFIT3
PDAC
VDAC2
post-translational modification
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
12
2019
accepted:
20
04
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
4
5
2021
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide and effective therapy remains a challenge. IFIT3 is an interferon-stimulated gene with antiviral and pro-inflammatory functions. Our previous work has shown that high expression of IFIT3 is correlated with poor survival in PDAC patients who receive chemotherapy suggesting a link between IFIT3 and chemotherapy resistance in PDAC. However, the exact role and molecular mechanism of IFIT3 in chemotherapy resistance in PDAC has been unclear.
Identifiants
pubmed: 32641986
doi: 10.7150/thno.43093
pii: thnov10p7178
pmc: PMC7330856
doi:
Substances chimiques
IFIT3 protein, human
0
Intracellular Signaling Peptides and Proteins
0
VDAC2 protein, human
0
Voltage-Dependent Anion Channel 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7178-7192Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Immunol. 2011 Sep 1;187(5):2559-68
pubmed: 21813773
Cancers (Basel). 2019 Jun 22;11(6):
pubmed: 31234517
Exp Mol Med. 2017 Dec 1;49(12):e406
pubmed: 29611542
PLoS One. 2013 Nov 04;8(11):e79518
pubmed: 24223959
Cell Host Microbe. 2013 Jun 12;13(6):701-10
pubmed: 23768494
Oncogene. 2019 Apr;38(17):3232-3247
pubmed: 30626937
Bioessays. 1999 Nov;21(11):932-9
pubmed: 10517866
Carcinogenesis. 2018 Oct 8;39(10):1222-1234
pubmed: 30052810
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Nucleic Acids Res. 2018 Jun 1;46(10):5269-5285
pubmed: 29554348
Nat Commun. 2019 Apr 23;10(1):1832
pubmed: 31015432
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Sci Rep. 2016 Sep 13;6:32994
pubmed: 27620692
Circ Res. 2008 Oct 24;103(9):983-91
pubmed: 18802025
Theranostics. 2020 Mar 4;10(9):3967-3979
pubmed: 32226532
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Stem Cells. 2011 Jan;29(1):32-45
pubmed: 21280157
Ann Oncol. 2017 Dec 1;28(12):2950-2961
pubmed: 28945842
Nat Genet. 2020 Feb;52(2):231-240
pubmed: 31932696
Cell Death Differ. 2003 Jul;10(7):853-5
pubmed: 12815469
Adv Cancer Res. 2018;138:41-69
pubmed: 29551129
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Pharmacol Ther. 2015 Nov;155:80-104
pubmed: 26299994
Oncotarget. 2015 Feb 20;6(5):3306-18
pubmed: 25650658
J Biol Chem. 2013 May 24;288(21):15121-30
pubmed: 23592772
Hepatology. 2017 Jul;66(1):152-166
pubmed: 28295457
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Front Mol Biosci. 2019 Dec 19;6:148
pubmed: 31921891
Nat Genet. 2015 Oct;47(10):1168-78
pubmed: 26343385
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Cell Death Dis. 2018 Apr 30;9(5):485
pubmed: 29706631
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8146-51
pubmed: 21540332
Ann Surg. 2018 May;267(5):936-945
pubmed: 28338509
Cell Rep. 2018 Nov 13;25(7):1741-1755.e7
pubmed: 30428345
BMC Biol. 2019 Jul 4;17(1):52
pubmed: 31272438
Clin Cancer Res. 2018 Mar 15;24(6):1344-1354
pubmed: 29288237
Neoplasia. 1999 Apr;1(1):50-62
pubmed: 10935470
Science. 2003 Jul 25;301(5632):513-7
pubmed: 12881569
Arthritis Rheumatol. 2018 Dec;70(12):2036-2045
pubmed: 29806091
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
J Biol Chem. 2018 Sep 7;293(36):13989-14000
pubmed: 30037904
J Cancer Res Clin Oncol. 2017 Jun;143(6):1061-1068
pubmed: 28210844
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Nat Rev Mol Cell Biol. 2017 Jul;18(7):452-465
pubmed: 28488703
Biochim Biophys Acta. 2016 Oct;1863(10):2503-14
pubmed: 27116927
Nat Commun. 2018 Nov 26;9(1):4976
pubmed: 30478310
Theranostics. 2018 May 11;8(12):3224-3236
pubmed: 29930725
Cell Death Differ. 2018 Jan;25(1):46-55
pubmed: 29053143
J Am Chem Soc. 2008 Sep 3;130(35):11576-7
pubmed: 18683930
Biochim Biophys Acta. 2012 Jun;1818(6):1520-5
pubmed: 22120575
J Biol Chem. 2011 Mar 4;286(9):7257-66
pubmed: 21190939
Mol Cancer Ther. 2015 Mar;14(3):788-98
pubmed: 25527634
Cell Rep. 2013 Oct 31;5(2):546-52
pubmed: 24120863
Cell Death Differ. 2014 Dec;21(12):1925-35
pubmed: 25146925